Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 560 participants.
Also called NCT05077683
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 560 participants
- Registry
-
NCT05077683 -
2021-001534-19
-
- Other papers using this trial's data
- Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction: The APERITIF Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- France
- Registry status
- Completed
Technical summary
Registry record NCT05077683. Randomized; no masking; primary purpose treatment. Start 2021-10-10 (actual); primary completion 2023-03-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF
- Acronym
- APERITIF
- Condition
- Myocardial Infarction, Acute
- Condition
- Left Ventricular Thrombus
- Intervention (Drug)
- Rivaroxaban 2.5 MG [Xarelto]
- Intervention (Drug)
- DAPT strategy
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
Record details
- Record id
cardio:ct-nct05077683- Content hash
824e8c5736b10e06078e1e36f37372ec1a622a29c6747951ae50d5507c43e4b7